Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Heather Symons, MD, MHS, Allen R. Chen, MD, PhD, MHS, M. Sue Leffell, PhD, Marianna Zahurak, M.S., Kathy Schultz, Heather Karaszkiewicz, Leo Luznik, MD, Javier Bolanos Meade, MD, Yvette L. Kasamon, MD, Lode J. Swinnen, MD, Douglas Edward Gladstone, MD, Richard J. Jones, MD, Ephraim Fuchs, MD, MBA

Blood (2010) 116 (21): 2362.

https://doi.org/10.1182/blood.V116.21.2362.2362

Published: 2010

Journal Articles

Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).

Blood (2007) 110 (11): 173.

https://doi.org/10.1182/blood.V110.11.173.173

Published: 2007

Journal Articles

Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors.

Paul O’Donnell, MD, PhD, Leo Luznik, MD, Heather Symons, MD, Richard Jones, MD, Ted Gooley, PhD, Elizabeth Harrington, MSN, Sandra Warnock, Brenda Sandmaier, MD, Rainer Storb, MD, Ephraim Fuchs, MD

Blood (2006) 108 (11): 3135.

https://doi.org/10.1182/blood.V108.11.3135.3135

Published: 2006

Journal Articles

Effect of Intravenous Busulfan Versus Total Body Irradiation on Donor Chimerism and Acute Graft-Versus-Host Disease (GVHD) after Allogeneic Stem Cell Transplantation (AlloSCT) in Mice.

Jie Wang, MD, Xiaotao Zhou, MS, Heather Symons, MD, Moshe Y. Levy, MD, Ephraim J. Fuchs, MD

Blood (2005) 106 (11): 5254.

https://doi.org/10.1182/blood.V106.11.5254.5254

Published: 2005

Journal Articles

Synergy between Nonmyeloablative Doses of Intravenous Busulfan and Post-Transplantation Cyclophosphamide for Induction of Tolerance to MHC-Compatible Stem Cell Allografts.

Xiaotao Zhou, MS, Jie Wang, MD, Moshe Y. Levy, MD, Heather Symons, MD, Ephraim J. Fuchs, MD

Blood (2005) 106 (11): 3040.

https://doi.org/10.1182/blood.V106.11.3040.3040

Published: 2005

NARROW

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).

Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors.

Effect of Intravenous Busulfan Versus Total Body Irradiation on Donor Chimerism and Acute Graft-Versus-Host Disease (GVHD) after Allogeneic Stem Cell Transplantation (AlloSCT) in Mice.

Synergy between Nonmyeloablative Doses of Intravenous Busulfan and Post-Transplantation Cyclophosphamide for Induction of Tolerance to MHC-Compatible Stem Cell Allografts.

Email alerts

ASH Publications

American Society of Hematology

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).

Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors.

Effect of Intravenous Busulfan Versus Total Body Irradiation on Donor Chimerism and Acute Graft-Versus-Host Disease (GVHD) after Allogeneic Stem Cell Transplantation (AlloSCT) in Mice.

Synergy between Nonmyeloablative Doses of Intravenous Busulfan and Post-Transplantation Cyclophosphamide for Induction of Tolerance to MHC-Compatible Stem Cell Allografts.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only